Entero Therapeutics, Stock Current Liabilities
| ENTO Stock | 0.45 0.01 2.17% |
Entero Therapeutics, fundamentals help investors to digest information that contributes to Entero Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Entero Stock. The fundamental analysis module provides a way to measure Entero Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entero Therapeutics, stock.
As of the 28th of November 2024, Total Current Liabilities is likely to drop to about 3 M. In addition to that, Non Current Liabilities Total is likely to drop to about 139.6 K. Entero | Current Liabilities |
Entero Therapeutics, Company Current Liabilities Analysis
Entero Therapeutics,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Entero Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Entero Therapeutics, is extremely important. It helps to project a fair market value of Entero Stock properly, considering its historical fundamentals such as Current Liabilities. Since Entero Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entero Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entero Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Entero Current Liabilities Historical Pattern
Today, most investors in Entero Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Entero Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Entero Therapeutics, current liabilities as a starting point in their analysis.
Entero Therapeutics, Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Entero Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Entero Therapeutics, has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Entero Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entero Therapeutics,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entero Therapeutics, could also be used in its relative valuation, which is a method of valuing Entero Therapeutics, by comparing valuation metrics of similar companies.Entero Therapeutics, is currently under evaluation in current liabilities category among its peers.
Entero Therapeutics, Current Valuation Drivers
We derive many important indicators used in calculating different scores of Entero Therapeutics, from analyzing Entero Therapeutics,'s financial statements. These drivers represent accounts that assess Entero Therapeutics,'s ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entero Therapeutics,'s important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 23.3M | 27.6M | 12.9M | 4.4M | 1.3M | 1.2M | |
| Enterprise Value | 23.3M | 22.2M | 5.7M | 3.9M | (1.6M) | (1.5M) |
Entero Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 66.34 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Shares Owned By Insiders | 7.20 % | ||||
| Shares Owned By Institutions | 5.98 % | ||||
| Number Of Shares Shorted | 152.93 K | ||||
| Price To Book | 0.07 X | ||||
| EBITDA | (15.74 M) | ||||
| Net Income | (15.79 M) | ||||
| Total Debt | 826.84 K | ||||
| Book Value Per Share | 7.99 X | ||||
| Cash Flow From Operations | (12.38 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (11.04) X | ||||
| Target Price | 36.0 | ||||
| Beta | 1.37 | ||||
| Market Capitalization | 1.11 M | ||||
| Total Asset | 6.88 M | ||||
| Retained Earnings | (184.33 M) | ||||
| Working Capital | 1.82 M | ||||
| Net Asset | 6.88 M |
About Entero Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entero Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entero Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entero Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Entero Stock
| 0.6 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.59 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.48 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.45 | RGNX | Regenxbio | PairCorr |
| 0.33 | PEPG | PepGen | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Entero Therapeutics, Piotroski F Score and Entero Therapeutics, Altman Z Score analysis. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.